- Home
- IONS vs ITRI Comparison
IONS vs ITRI Comparison
Compare IONS & ITRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IONS
- ITRI
- Stock Information
- Founded
- IONS 1989
- ITRI 1977
- Country
- IONS United States
- ITRI United States
- Employees
- IONS N/A
- ITRI N/A
- Industry
- IONS Biotechnology: Pharmaceutical Preparations
- ITRI Electrical Products
- Sector
- IONS Health Care
- ITRI Industrials
- Exchange
- IONS Nasdaq
- ITRI Nasdaq
- Market Cap
- IONS 6.8B
- ITRI 6.2B
- IPO Year
- IONS 1991
- ITRI 1993
- Fundamental
- Price
- IONS $69.15
- ITRI $127.18
- Analyst Decision
- IONS Strong Buy
- ITRI Strong Buy
- Analyst Count
- IONS 18
- ITRI 9
- Target Price
- IONS $72.83
- ITRI $137.00
- AVG Volume (30 Days)
- IONS 2.2M
- ITRI 722.1K
- Earning Date
- IONS 11-05-2025
- ITRI 10-30-2025
- Dividend Yield
- IONS N/A
- ITRI N/A
- EPS Growth
- IONS N/A
- ITRI 44.31
- EPS
- IONS N/A
- ITRI 5.85
- Revenue
- IONS $944,050,000.00
- ITRI $2,442,238,000.00
- Revenue This Year
- IONS $24.01
- ITRI N/A
- Revenue Next Year
- IONS $4.06
- ITRI $5.52
- P/E Ratio
- IONS N/A
- ITRI $21.43
- Revenue Growth
- IONS 16.05
- ITRI 3.90
- 52 Week Low
- IONS $23.95
- ITRI $90.11
- 52 Week High
- IONS $69.25
- ITRI $140.04
- Technical
- Relative Strength Index (RSI)
- IONS 80.12
- ITRI 60.20
- Support Level
- IONS $61.03
- ITRI $121.33
- Resistance Level
- IONS $63.18
- ITRI $125.51
- Average True Range (ATR)
- IONS 1.63
- ITRI 2.64
- MACD
- IONS 0.02
- ITRI 0.67
- Stochastic Oscillator
- IONS 89.41
- ITRI 90.06
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
About ITRI Itron Inc.
Itron Inc provides solutions that measure, manage, and analyze energy and water use. It operates under the Itron brand and manages and reports under three operating segments: Device Solutions, Networked Solutions, and Outcomes. The Device Solutions segment includes hardware products used for measurement, control, or sense that do not have communications capability embedded for use with broader Itron systems. The Networked Solutions segment includes a combination of communicating devices, network infrastructure, and associated application software designed and sold as a complete solution. The Outcome segment includes their value-added, enhanced software and services which manage, organize, analyze, and interpret data to improve decision-making and maximize operational profitability.